Open AccessTwo years progression-free survival under vinorelbine metronomic therapy of a patient with metastatic epithelioid hemangioendothelioma
Author(s) -
Stavros Anevlavis,
Georgia Karpathiou,
Paschalis Ntolios,
Marios Froudarakis
Publication year - 2022
Publication title -
monaldi archives for chest disease. pulmonary series/monaldi archives for chest disease/monaldi archives for chest disease. cardiac series
Language(s) - English
Resource type - Journals
eISSN - 2465-101X
pISSN - 1122-0643
DOI - 10.4081/monaldi.2022.1798
Subject(s) - vinorelbine , medicine , epithelioid hemangioendothelioma , population , oncology , hemangioendothelioma , pathology , surgery , chemotherapy , cisplatin , immunohistochemistry , environmental health
Epithelioid hemangioendothelioma (EHE) is a very rare vascular tumor, originating from endothelial cells. The etiology of EHE is unknown, yet at the molecular level, different angiogenic stimulators may act as promoters of endothelial cell proliferation. The tumor affects more commonly the lung, the liver and the bones but it can affect any other organ. Due to its heterogeneous presentation and its rarity it is often misdiagnosed. No treatment is proved to be efficient in metastatic EHE and the median survival of patients with metastatic pleural disease is generally poor, less than one year. we report a case of a 57-year-old female with multiple metastatic EHE including pleural, diagnosed by medical thoracoscopy, with a progression-free survival of 24 months with oral vinorelbine as maintenance therapy after combination of cisplatin-vinorelbine. We believe that this therapy might be of value to test in this patient population as it has never been tested before.